Abstract

Abstract The need for novel therapies for glioblastoma multiforme (GBM) is well established. Chimeric antigen receptor (CAR)-engineered T cells represent a promising cancer treatment modality for treating GBM. However, CAR-T therapy has limitations, such as low penetration into solid tumors and short duration of CAR-T survival. Protein phosphatase 2A (PP2A) inhibition has been implicated in enhancing T cell anti-tumor activity. LB-100 is a novel, first-in-class, small molecule inhibitor of PP2A recently shown in a Phase I trial to be well-tolerated at doses resulting in stabilization of progressive solid tumors. We set out to overcome limitations of CAR-T therapy by activating the mTOR signaling pathway through inhibition of PP2A by LB-100. GBM highly expresses CAIX due to increased hypoxia signaling. Thus, antitumor CAIX-specific CAR T cells were developed and tested against GBM in vitro and in vivo. CAR-T cells displayed GBM cells cytotoxicity and increased IFN-γ, TNF-α, and IL-2 production. Intra-tumor injection of the CAR-T cells into an intracranial GBM xenograft mouse model efficiently suppressed the tumor growth. We found that PP2A inhibition by LB-100 further enhanced CAIX CAR-T activity and significantly prolonged mouse survival. Herein we demonstrate that CAIX represents a viable target for CAR-T cells and inhibition of PP2A enhances CAR-T efficacy against GBM. Targeting PP2A via inhibition with LB-100 may be a promising therapeutic strategy to improve CAR-T efficacy in other solid tumors. Citation Format: Jing Cui, Qi Zhang, Qi Song, Herui Wang, Pauline Dmitriev, Mitchell Sun, Jared S. Rosenblum, Kaiyong Yang, John Kovach, Mark R. Gilbert, Zhengping Zhuang. Targeting PP2A with LB100 enhances efficacy of CAIX CAR-T cells against GBM [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2260.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call